European Patent Office Dismisses Arguments by Regeneron
Favorable Rulings Further Strengthen IP Estate in Europe and Japan through 2029

UTRECHT, The Netherlands, Nov. 15, 2016 (GLOBE NEWSWIRE) –

Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that it received two favorable rulings for its European patent EP 2147594 B1 (the “‘594 patent”) by the Opposition Division of the European Patent Office (the “EPO”) as well by the Trial Board of the Japanese Patent Office for its Japanese counterpart JP 5749161 (the “‘161 patent”). Both patents cover Merus’ genetically-modified mice and their use to produce common light chain human monoclonal antibodies.

Read the full news release